• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by Cel-Sci Corporation

    5/18/26 7:18:56 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CVM alert in real time by email
    RW 1 cvm_rw.htm FORM RW cvm_rw.htm

     

    HART & HART, LLC

    ATTORNEYS AT LAW

    1624 Washington Street

    Denver, CO  80203

    ________

    Facsimile: (303) 839-5414

    (303) 839-0061

     

    May 18, 2026

     

    Securities and Exchange Commission

    100 F Street, NE

    Washington, DC 20549

     

     

    Re:

    CEL-SCI Corporation

    Post-Effective Amendment to Registration Statement on Form S-3

    File No. 333-265995

     

    This office represents CEL-SCI Corporation (the "Company"). On behalf of the Company, we request that the above-captioned registration statement be withdrawn. The reason for this request is that the Post-Effective Amendment was filed in error.

     

    No securities were sold by means of the Post-Effective Amendment to the Registration Statement.

     

      Very Truly Yours,

     

    HART & HART, LLC

           
    By /s/ William T. Hart

     

     

    William Hart  

     

    Get the next $CVM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CEL-SCI Reports Fiscal Second Quarter 2026 Results

    On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026 Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia 50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation CEL-SCI's CEO continues to invest in the Company acquiring a cumulative ~$930,000 worth of stock over the past 10 months CEL-SCI Corporation (NYSE:CVM) today reported financial results for three months ended March 31, 2026, as well as key recent corporate, commercial, regulatory, and clinical developments for Multikine (Leukocyte Interleukin, Injection)*. "Durin

    5/18/26 8:00:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Announces Closing of Public Offering

    CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts public offering of 6,000,000 shares of its common stock. Each share of common stock was sold at a public offering price of $1.20 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $7.2 million. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offering. A registration statement on

    5/13/26 3:00:00 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Corporation Announces Pricing of Public Offering

    CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000 shares of its common stock at an offering price of $1.20 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and offering expenses, are expected to be approximately $7.2 million. The offering is expected to close on May 13, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the proceeds for the continued development of Multikine*, general corporate purposes, and working capital. ThinkEquity is acting as the sole placement agen

    5/11/26 8:11:00 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kersten Geert R bought $360,000 worth of shares (300,000 units at $1.20) (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    5/18/26 8:03:20 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kersten Geert R bought $119,000 worth of shares (100,000 units at $1.19), increasing direct ownership by 82% to 222,497 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    5/14/26 8:56:53 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/26/26 8:23:27 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kersten Geert R bought $360,000 worth of shares (300,000 units at $1.20) (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    5/18/26 8:03:20 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kersten Geert R bought $119,000 worth of shares (100,000 units at $1.19), increasing direct ownership by 82% to 222,497 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    5/14/26 8:56:53 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Talor Eyal

    4 - CEL SCI CORP (0000725363) (Issuer)

    4/1/26 7:08:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    SEC Filings

    View All

    SEC Form RW filed by Cel-Sci Corporation

    RW - CEL SCI CORP (0000725363) (Filer)

    5/27/26 5:00:36 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form RW filed by Cel-Sci Corporation

    RW - CEL SCI CORP (0000725363) (Filer)

    5/18/26 7:18:56 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Cel-Sci Corporation

    10-Q - CEL SCI CORP (0000725363) (Filer)

    5/15/26 5:00:50 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Leadership Updates

    Live Leadership Updates

    View All

    CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

    CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This

    8/15/24 8:00:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Appoints Robert Watson as Chairperson of the Board

    CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in

    7/8/24 9:15:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Appoints Mario Gobbo to Its Board of Directors

    CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation

    4/23/24 9:00:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

    SC 13G/A - CEL SCI CORP (0000725363) (Subject)

    2/8/23 10:48:28 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

    SC 13G/A - CEL SCI CORP (0000725363) (Subject)

    4/11/22 1:55:14 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

    SC 13G/A - CEL SCI CORP (0000725363) (Subject)

    2/11/22 7:53:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care